08:12 AM EDT, 09/18/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Wednesday that long-term data from a phase 3 study of Zeposia, or ozanimod, support the drug's efficacy and safety in patients with relapsing forms of multiple sclerosis.

The company said patients who received Zeposia treatment for up to five years saw low and stable rates of whole brain volume loss.

More than eight years of data also revealed declining or stable incidence rates of treatment-emergent adverse events, with relatively low rates of infections, according to Bristol-Myers.

Price: 49.59, Change: +0.10, Percent Change: +0.20